Abiomed

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

PreCardia specializes in the development of partially implantable devices aimed at treating patients with acute decompensated heart failure (ADHF). The company's innovative approach involves intermittent occlusion of the superior vena cava, which helps to reduce venous return to the heart. This method is designed to address critical hemodynamic targets associated with ADHF, ultimately enhancing patient outcomes in inpatient settings.

Breethe, Inc. is a medical device company based in Baltimore, Maryland, that specializes in the development and commercialization of wearable artificial lungs for patients with acute and chronic respiratory issues. Its flagship product, the OXY-1 System, is a portable device that assists in blood circulation and gas exchange, effectively functioning like a human lung. This technology allows patients suffering from respiratory failure to receive necessary ECMO therapy while maintaining mobility, eliminating the dependence on cumbersome oxygen tanks. Founded in 2014, Breethe aims to improve treatment outcomes for individuals facing end-stage lung failure. The company operates as a subsidiary of Abiomed, Inc.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Protembis GmbH, founded in 2017 and based in Aachen, Germany, specializes in the manufacture of surgical equipment aimed at enhancing the safety of transcatheter aortic valve replacement (TAVR) procedures. The company has developed the ProtEmbo System, an intra-aortic filter device designed to mitigate the risk of cerebrovascular events during TAVR by deflecting embolic material away from the cerebral circulation. This innovation addresses a significant complication associated with TAVR, which has become a preferred treatment for patients with valvular heart disease, particularly as the procedure is increasingly performed on younger and lower-risk individuals. By minimizing the risk of brain injury, Protembis aims to improve patient outcomes and reduce healthcare costs related to surgical complications.

RenalGuard Solutions, Inc. specializes in manufacturing medical devices aimed at the cardiac and vascular markets. Its flagship product, RenalGuard, is designed to remove contrast dyes that can be harmful to the kidneys in at-risk patients undergoing specific imaging procedures. The company offers RenalGuard Therapy, which mitigates the toxic effects of contrast media, potentially decreasing the incidence of contrast-induced nephropathy (CIN). The RenalGuard System includes a console and a single-use set for infusion and urine collection. RenalGuard is already approved for sale in the European Union for general fluid balancing and has shown effectiveness in preventing CIN in two European studies. Additionally, it is currently undergoing a pivotal trial in the United States as part of the FDA approval process. RenalGuard Solutions distributes its products through a network of distributors both domestically and internationally, and it is headquartered in Milford, Massachusetts.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

ALung Technologies is a medical device manufacturing company based in Pittsburgh, Pennsylvania, founded in 1997. The company specializes in developing devices for gas exchange to treat acute and chronic respiratory disorders. Its primary product, the Hemolung Respiratory Assist System (RAS), functions as a dialysis-like alternative or supplement to mechanical ventilation, allowing physicians to effectively remove carbon dioxide from the blood without relying solely on the lungs. This technology aims to reduce the need for intubation and invasive ventilation, thereby improving patient outcomes. Additionally, ALung offers the Hattler Catheter, which facilitates the insertion of its gas exchange devices into the central venous bloodstream.

ECP Entwicklungsgesellschaft is a a medical device company and is developing a product that is a percutaneous, expandable catheter pump which increases blood circulation from the heart with an external drive shaft.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.